Limbal Stem Cell Deficiency
Conditions
Brief summary
This study will enroll subjects with qualifying limbal stem cell deficiency (LSCD). All subjects will receive CSB-001 investigational drug in either one or both study eyes. The study is comprised of two identical phases (Dosing Phase I and II) of test article dosing separated by a 31- to 40-day period, the Dosing Holiday, where no test article is administered. Dosing Phase II is followed by an observational, noninterventional phase (Observation Phase).
Interventions
BIOLOGICALCSB-001 Ophthalmic Solution 0.1%
CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)
Sponsors
Claris Biotherapeutics, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have an area of the central 5 mm zone of cornea affected, presence of at least one clinical sign observed by slit-lamp examination with white light and/or cobalt blue light, fluorescein, and a Wratten filter, and at least one clinical sign observed with AS-OCT. * If dosing with Acthar at time of Screening Visit, must have a history of stable dosing for approximately 8 weeks, plan to maintain the same Acthar treatment dose and regimen, and have demonstrated little to no improvement in severity of LSCD. * Sponsor written confirmation of qualifying LSCD diagnosis. * Inflammation associated with LSCD or other non-infectious inflammation that will not interfere with subject's participation.
Exclusion criteria
* Any active ocular infection (bacterial, viral, fungal, or protozoan) in either eye. * Ocular surgery within 30 days of Day 0 where investigator assesses that healing is not considered complete/stable. * Planned ocular surgery on or before Week 20 visit. * Presence or history of any ocular or systemic disorder, condition, or procedure that might hinder the efficacy of the study treatment or its evaluation, or could interfere with the interpretation of study results, in the opinion of the investigator. Note: Other inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety as Assessed by Adverse Event Reporting | Day 0 through Week 144 | Incidence of ocular and systemic adverse events |
| Safety as Assessed by Slit-lamp Biomicroscopy | Day 0 through Week 144 | Change from baseline in slit-lamp parameters |
| Safety as Assessed by Best-corrected Distance LogMAR Visual Acuity | Day 0 through Week 144 | Change from baseline using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy as Assessed by Change in Stage of LSCD | Day 0 through Week 144 | Change from baseline in LSCD signs based on imaging (white light, blue light with fluorescein and Wratten filter, and AS-OCT) |
| Efficacy as Assessed by Change in Best-corrected Distance LogMAR Visual Acuity | Day 0 through Week 144 | Visual acuity measured using the EDTRS visual acuity chart |
Countries
United States
Contacts
CONTACTCentral Operations Representative
Outcome results
None listed